BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:38 PM
 | 
Sep 24, 2012
 |  BC Extra  |  Company News

Valeant acquires Visudyne from QLT

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired rights to ophthalmic product Visudyne verteporfin from QLT Inc. (TSX:QLT; NASDAQ:QLTI) for $112.5 million up front. QLT is also eligible to receive up to...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >